Clinical Data Standards Governance. Tammy Burns, Expert Clinical Data Manager 11 th January 2013

Size: px
Start display at page:

Download "Clinical Data Standards Governance. Tammy Burns, Expert Clinical Data Manager 11 th January 2013"

Transcription

1 Clinical Data Standards Governance Tammy Burns, Expert Clinical Data Manager 11 th January 2013

2 Standards Used and Formal Govenance Standard Types General and Therapeutic Area Data Standards Collection Modules EMD Serono/Merck Serono SDTM Standards EMD Serono/Merck Serono ADaM Standards Controlled Terminology Value Level Metadata GBS Output Standards Standard algorithms The official CDISC Standards Standard validated programs and tools Standard mappings 2 Clinical Data Standards Governance

3 Objective of the WI To describe the management of the general and therapeutic area data standards, Study Data Tabulation Model (SDTM) and Analysis Data Model (ADaM) in relation to the creation, use, maintenance and documentation of the standards, to ensure data consistency and to facilitate regulatory submissions 3 Clinical Data Standards Governance

4 Standards Governance Requires empowerment of governance teams to reinforce the standards within the organisation and a strong support from upper management It requires the governance teams to be advocates for the use of standards increasing the acceptance across the organisation Allocating resources for standards management is a must to achieve the benefits 4 Clinical Data Standards Governance

5 Governance Teams Standards Governance Teams General Data Standards (DS) Team Therapeutic Area Data Standards (TA DS) Team for each of the main Therapeutic Areas Membership DS Team Lead Clinical Data Standards Librarian(s) Controlled Terminology Librarian TA DS Team Lead Controlled Terminology Librarian Merck Serono (MS) SDTM Team Merck Serono (MS) ADaM Team SDTM Team Lead (appointed by the Head of Global Clinical Data Science or designee) SDTM Librarian(s) Controlled Terminology Librarian MS ADaM Team Representative appointed by the MS ADaM Team Lead MS ADaM Team Lead (appointed by the Head of Global Biostatistics or designee) Statistical Standards Librarian (ADaM) Statistical Programmer(s) Biostatistician(s) 5 Presentation title in footer 00 Month 0000

6 Standards Governance Teams (ctd) Organisation Level Function EMD Serono/Merck Serono Clinical Governance Head of GDM and GBS Standard Type General Data Standards Team TA Data Standards Team SDTM Team ADaM Team Project PDM PDM Specialist / PDM Specialist /Project Stats Prog / Biostat Trial TDM CRO TDM CRO TDM CRO Trial Stats Prog Trial Biostat CRO 6 Clinical Data Standards Governance

7 When is the governance process used? Previous governance only required an exemption when not complying with the existing standard. Study specific forms did not require approval/governance process. The new governance requires if the current clinical data standards do not cover all the requirements for setting up any of the trial specifications (e.g. ecrf, SDTM, ADaM) or anything which does not comply with an existing standard a New, Change or Exemption Request Form is completed and approved prior to implementation. 7 Clinical Data Standards Governance

8 Completion of Metadata on the Clinical Data Standards New, Change or Exemption Request Form When the governance was updated to incorporate the governance of SDTM, CT and ADaM Standards it was felt that the SDTM metadata should be provided as early as when the CRFs were being designed We then agreed to take a flexible approach to the completion of the New, Change or Exemption form so that the process can be adapted to what is required and what is feasible. Definition of all metadata is now not required at the CRF creation phase. However, where possible, the minimum information should be collected (i.e. CT and VLM) and an SDTM Expert should review the request to evaluate the impact on the SDTM 8 Clinical Data Standards Governance

9 When, How Much and Where Do We Govern How do we balance strict timelines for go-live of a CRF with time to manage and mandate the use of standards? Do we govern the SDTM at the same time as the General Clinical Data Collection Standards? Do we govern all forms and modules including study specific? 9 Clinical Data Standards Governance

10 Standards and Governance Team Objectives Development of new standards Assessing the impact of new releases of CDISC standards and related guidance from Health Authorities on the company specific standards Freezing standards which are no longer in use Providing general rules and conventions for company specific use of general data standards, control terminology, CDISC SDTM and ADaM, as applicable Develop and provide training 10 Clinical Data Standards Governance

11 Standards and Governance Team Objectives Providing expert guidance on the application of the standards Compliance to existing standards Management of exemptions Track all exemptions and review them for potential changes to the standards Track and review all requests for updates to the standards and make the changes or provide rationale as to why a request is not made 11 Clinical Data Standards Governance

October, Integration and Implementation of CDISC Standards

October, Integration and Implementation of CDISC Standards Integration and Implementation of CDISC Standards October, 2008 Barbara Lentz, Associate Director, Electronic Data Management Standards, Processes & Training Pat Majcher, Statistical Reporting Services

More information

CDISC Data Standards Validation

CDISC Data Standards Validation CDISC Data Standards Validation How can it be done? Peter Van Reusel Business Unit Director Business & Decision Life Sciences Tel +32 2 774 11 00 Fax +32 2 774 11 99 Mobile +32 476 54 59 17 peter.vanreusel@businessdecision.com

More information

Roadmap for Managing Multiple CRO Vendors

Roadmap for Managing Multiple CRO Vendors PharmaSUG 2017 - Paper PO27 Roadmap for Managing Multiple CRO Vendors Veena Nataraj, Shire, Lexington, MA Karin LaPann, Shire, Lexington, MA ABSTRACT When working with CROs, the relationship established

More information

End-to-End Management of Clinical Trials Data

End-to-End Management of Clinical Trials Data End-to-End Management of Clinical Trials Data A Revolutionary Step Toward Supporting Clinical Trials Analysis Over the Next Decades of Clinical Research WHITE PAPER SAS White Paper Table of Contents Introduction....

More information

CDASH Clinical Data Acquisition Standards Harmonization

CDASH Clinical Data Acquisition Standards Harmonization CDISC Italian User Group Meeting 16 November 2007 CDASH Clinical Data Acquisition Standards Harmonization 1 Outline Background Organization Goals Timelinesand Process Review of progress Results Future

More information

Aepodia is a team of experts with more than 15 years

Aepodia is a team of experts with more than 15 years Aepodia is a team of experts with more than 15 years experience in early clinical development and translational science with small startup and large global pharmaceutical companies. Aepodia s team has

More information

PharmaSUG Paper PO12

PharmaSUG Paper PO12 PharmaSUG 2016 - Paper PO12 CDISC Standards End-to-End: Transitional Hurdles Alyssa Wittle, Chiltern International, King of Prussia, PA Christine McNichol, Chiltern International, King of Prussia, PA Antonio

More information

CDASH 2.0. Berlin Éanna Kiely CDISC Engineer

CDASH 2.0. Berlin Éanna Kiely CDISC Engineer CDASH 2.0 Berlin Éanna Kiely CDISC Engineer 2016-09-13 Agenda CDASH 1.1 & CDASHIG 2.0 CDASH Concepts TAUG Examples Current Regulatory Perspective on CDASH Questions 2 CDASH: CDISC End to End Clinical Data

More information

Chapter 1. Pharmaceutical Industry Overview

Chapter 1. Pharmaceutical Industry Overview Chapter 1 Pharmaceutical Industry Overview 1.1 Introduction 2 1.2 Regulations 2 1.2.1 Health Insurance Portability and Accountability Act 2 1.2.2 The Code of Federal Regulations 3 1.2.3 Guidance for Industry

More information

PharmaSUG 2017 Paper DS14

PharmaSUG 2017 Paper DS14 PharmaSUG 2017 Paper DS14 Considerations in Submitting Standardized Electronic Data Under the Animal Rule: The Use of SDTMIG and SENDIG Domains, and the Need for New Domains and Concepts Fred Wood, Accenture

More information

Clinical Data Acquisition Standards Harmonization (CDASH)

Clinical Data Acquisition Standards Harmonization (CDASH) Clinical Data Acquisition Standards Harmonization () Prepared by: CDISC Team Section Table of Contents Page 1.0 Orientation... 1 1.1 Purpose... 1 1.2 Organization of this Document... 1 1.2.1 General Notes...2

More information

The use of electronic Health Records in Clinical Research - The value of CDISC Standards

The use of electronic Health Records in Clinical Research - The value of CDISC Standards The use of electronic Health Records in Clinical Research - The value of CDISC Standards FH-Prof. Dr. Jozef Aerts University of Applied Sciences FH Joanneum Graz, Austria Who is Jozef Aerts? CDISC volunteer

More information

CDISC UK Network face to face Reading

CDISC UK Network face to face Reading CDISC UK Network face to face Reading Paul Houston, CDISC Head of European Operations CDISC Update and European Activity 2 CDISC Values and Principals Core value Foster CDISC community is altruistic

More information

Data Integrity in Clinical Trials the Sponsor Perspective

Data Integrity in Clinical Trials the Sponsor Perspective Data Integrity in Clinical Trials the Sponsor Perspective Maximilian Stroebe, GSK Vaccines Three differences to Commercial Manufacturing Long process chains Source Data, Clinical Sites and Outsourcing

More information

Statistical Review and Data Standards: It s Gettin Better All The Time

Statistical Review and Data Standards: It s Gettin Better All The Time Statistical Review and Data Standards: It s Gettin Better All The Time Steve Wilson, Dr.P.H., CAPT USPHS Office of Biostatistics FDA/OMPT/CDER 2017 PharmaSUG Baltimore, MD May 17, 2017 Disclaimer This

More information

Electronic Health Records and Clinical Data Interchange Standards

Electronic Health Records and Clinical Data Interchange Standards Electronic Health Records and Clinical Data Interchange Standards Stephen E. Wilson, Dr.P.H., CAPT USPHS Director Division of Biostatistics III Center for Drug Evaluation and Research US Food and Drug

More information

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, F2/SM D (2008) QUESTIONS and ANSWERS The rules governing medicinal products in the European Union VOLUME 2 NOTICE

More information

Department At-A-Glance

Department At-A-Glance Integrated Site Services Functional Role Integrated Site Services (ISS) includes global and country Start-Up and Regulatory units (RSU) and Integrated Patients & Site Services (IPSS). Our department s

More information

Applying SDTM and ADaM to the Construction of Datamarts in Support of Cross-indication Regulatory Requests

Applying SDTM and ADaM to the Construction of Datamarts in Support of Cross-indication Regulatory Requests Applying SDTM and ADaM to the Construction of Datamarts in Support of Cross-indication Regulatory Requests Data-what? This presentation will discuss some of the complexities involved when integrating study

More information

Relevant Standards: Standards for Registered Training Organisations (RTOs) 2015: Transition of training products

Relevant Standards: Standards for Registered Training Organisations (RTOs) 2015: Transition of training products Australian Computer Society Policies and Procedures: Manage transition from superseded training Relevant Standards: Standards for Registered Training Organisations (RTOs) 2015: 1.26-1.27 Transition of

More information

Guidelines for Developing Randomization Procedures R03

Guidelines for Developing Randomization Procedures R03 Guidelines for Developing Randomization Procedures R03 Table of Contents 1. Purpose 2. Objective 3. Process 4. Description of Outputs 5. Field Procedures for a Double Blind Trial Involving the Research

More information

LOINC in Regulated Clinical Research a Lab LOINC Steeringg Committee Meeting 08 June 2017

LOINC in Regulated Clinical Research a Lab LOINC Steeringg Committee Meeting 08 June 2017 LOINC in Regulated Clinical Research a Lab LOINC Steeringg Committee Meeting 08 June 2017 Lauren Becnel, Ph.D. VP, Biomedical Informatics & Alliances, CDISC Asst Prof, Duncan Comprehensive Cancer Center,

More information

DATA SHARING AGREEMENT

DATA SHARING AGREEMENT DATA SHARING AGREEMENT Effective Date: This Data Sharing Agreement ( Agreement ) is effective as of the Effective Date between EMD Serono, One Technology Place, Rockland, MA 02370 and Name ( Institution

More information

INVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)

INVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used) INVESTIGATIONAL DEVICE EXEMPTION APPLICATION IDE Title (if title being used) Name of Sponsor Investigator, MD X Professor, Department Icahn School of Medicine at Mount Sinai Date of Submission Form version

More information

Optimizing Your Study Data Submissions to FDA Updates from CDER and CBER

Optimizing Your Study Data Submissions to FDA Updates from CDER and CBER This single PDF file contains the slides for all three presentations in the webinar: Optimizing Your Study Data Submissions to FDA Updates from CDER and CBER Please page down to find the slides for all

More information

PhilaSUG Spring 2007 Meeting Wednesday, June 13 th

PhilaSUG Spring 2007 Meeting Wednesday, June 13 th Spring 2007 Meeting Announcement PhilaSUG Spring 2007 Meeting Wednesday, June 13 th The Philadelphia Area SAS Users Group Spring Meeting will be on Wednesday, June 13, 2007 at 1:00 PM, and will be hosted

More information

Swiss Multiple Sclerosis Society Rules of Procedure for the Scientific Advisory Board

Swiss Multiple Sclerosis Society Rules of Procedure for the Scientific Advisory Board Swiss Multiple Sclerosis Society Rules of Procedure for the Scientific Advisory Board Based on Art. 8 of the Statutes, the following Rules of Procedure for the Scientific Advisory Board (SAB) are adopted:

More information

Public release of clinical information in drug submissions and medical device applications

Public release of clinical information in drug submissions and medical device applications Public release of clinical information in drug submissions and medical device applications Health Products and Food Branch March 10, 2017 Health Canada is the federal department responsible for helping

More information

An Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America

An Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America An Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America SPEAKERS: Janett Mugaburu-Richards, M.S. Pfizer Inc. Kavita Ramalingam Iyer, Ph.D Merck & Co., Inc. Contents

More information

Standard for Exchange of Nonclinical Data Implementation Guide: Nonclinical Studies

Standard for Exchange of Nonclinical Data Implementation Guide: Nonclinical Studies Standard for Exchange of Nonclinical Data Implementation Guide: Nonclinical Studies Prepared by the CDISC Standard for Exchange of Nonclinical Data Team Notes to Readers This is the implementation guide

More information

CHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS

CHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS Clinical Trial Supply 28 th 29 th October 2014 Princeton, NJ - USA CHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS 1 Agenda The challenges associated with various

More information

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Nancy Detich, Ph.D., C.C.R.P. Senior Scientist, Clinical Strategy 18 November 2010 1 Objectives Identify the importance of accuracy,

More information

White Paper INTRODUCING A COMPLEXITY SCORING SYSTEM IN CONTRACT NEGOTIATION

White Paper INTRODUCING A COMPLEXITY SCORING SYSTEM IN CONTRACT NEGOTIATION White Paper INTRODUCING A COMPLEXITY SCORING SYSTEM IN CONTRACT NEGOTIATION Table of Contents 1. Introduction... 3 2. The Key Drivers For Study Startup Performance... 3 3. Contracts Negotiation Parallel

More information

OCTC 2012 CRO Selection

OCTC 2012 CRO Selection OCTC 2012 CRO Selection Colin Macaulay Viron Therapeutics Inc. 15 Nov 2012 Viron Therapeutics Inc. Virtual Biotech Company (6) Phase 2a (48 pt) clinical trial in acute coronary syndrome (ACS) completed

More information

Safety Measures in the new Pharmacovigilance System

Safety Measures in the new Pharmacovigilance System Safety Measures in the new Pharmacovigilance System Dr. Harald Tietz Director Global Patient Safety & Regulatory Affairs, Germany Lilly Deutschland GmbH Documentation and reporting requirements: Centralisation

More information

EAUTIFUL BDATA AGGREGATION EXTRAVAGANZA. Implementing a Clinical Data Repository and Analytics Platform in 90 Days

EAUTIFUL BDATA AGGREGATION EXTRAVAGANZA. Implementing a Clinical Data Repository and Analytics Platform in 90 Days DATA IS SIMPLY EAUTIFUL BDATA AGGREGATION EXTRAVAGANZA This artful imagery is an abstract representation of data coming from a myriad of sources to create a single, impactful image. Created by data artist,

More information

Introduction to Clinical Research

Introduction to Clinical Research Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that

More information

HITSP Construct HL7 Standard

HITSP Construct HL7 Standard EHR Lab Results Reporting HL7 /IS01 Clinical Document Architecture Release 2 (CDA R2) /C37 - Lab Report Document U.S. Realm - Interoperability Specification: Lab Result to EHR (ORU^R01) (HL7.1) September,

More information

Life Sciences Regulatory Publishing Software Suite

Life Sciences Regulatory Publishing Software Suite Easily manage submissions across multiple regions Solution Suite Overview Life sciences companies today are challenged by regulatory submissions processes that vary by country and region. The DXC Technology

More information

CFAST Therapeutic Area Program Steering Committee 2013 Meeting Summaries (January-August)

CFAST Therapeutic Area Program Steering Committee 2013 Meeting Summaries (January-August) CFAST Therapeutic Area Program Steering Committee 2013 Meeting Summaries (January-August) Participant full names and titles: Wayne: Wayne Kubick, Chief Technology Officer, CDISC (Chair) Becky: Rebecca

More information

EU Portal and Database Update

EU Portal and Database Update EU Portal and Database Update TOPRA 4 October 2017 Presented by Noémie Manent on 4 October 2017 Committees and Inspections Department An agency of the European Union Table of content EMA Portal and Database

More information

The SDTMIG: What s New in 3.2

The SDTMIG: What s New in 3.2 Accenture Life Sciences Rethink Reshape Restructure for better health outcomes. The SDTMIG: What s New in 3.2 Fred Wood Data Standards Consulting Lead Accenture Life Sciences RTP CDISC User Network March

More information

Building (Earthquake-prone buildings) Amendment Bill Interim Report

Building (Earthquake-prone buildings) Amendment Bill Interim Report < Local Councils play an active role in keeping our communities safe.> Building (Earthquake-prone buildings) Amendment Bill Interim Report Local Government New Zealand s submission to Local Government

More information

Welcome to the American College of Toxicology s Webinar Series. We will begin at 11AM EDT

Welcome to the American College of Toxicology s Webinar Series. We will begin at 11AM EDT Welcome to the American College of Toxicology s Webinar Series We will begin at 11AM EDT Preparing for Nonclinical edata Regulatory Submissions to the US FDA SEND and Beyond September 5, 2013, 11:00 AM

More information

Job Evaluation Policy

Job Evaluation Policy Job Evaluation Policy (Revised 1 June 2013) 1. Aims The University uses a single job evaluation system for all categories of job, in order to: - Establish the relative size of all jobs. - Enable all jobs

More information

PK-PD Concepts and Programming Bangalore, India. 6th December India SDE

PK-PD Concepts and Programming Bangalore, India. 6th December India SDE PK-PD Concepts and Programming Bangalore, India 6th December 2014 India SDE 2014 1 Welcome Dear Single Day Event Attendee, We, on behalf of the organising committee would like to welcome you all to this

More information

Specific pathologist responses for Standard for Exchange of Nonclinical Data (SEND)

Specific pathologist responses for Standard for Exchange of Nonclinical Data (SEND) J Toxicol Pathol 2017; 30: 201 207 Review Specific pathologist responses for Standard for Exchange of Nonclinical Data (SEND) Atsushi Watanabe 1, 2*, Osamu Kusuoka 1, Norihiro Sato 1, Osamu Nakazono 1,

More information

Procurement procedure decision trees

Procurement procedure decision trees Procurement procedure decision trees Procurement procedure 1 Infrastructure: A staged is typically appropriate when: methods for a staged delivery model Scale is small to medium. Complexity, uncertainty

More information

CMC Strategy Forum Prague Enda Moran EBE Satellite Session, 06 May 2013

CMC Strategy Forum Prague Enda Moran EBE Satellite Session, 06 May 2013 CMC Strategy Forum Prague 2013 Enda Moran EBE Satellite Session, 06 May 2013 European Biopharmaceutical Enterprises EBE s VISION: fostering innovation, and promote favorable business and regulatory conditions

More information

PharmaSUG PO14

PharmaSUG PO14 PharmaSUG 2014 - PO14 Route to SDTM Implementation in In-Vitro Diagnostic Industry: Simple or Twisted Carey Smoak, Roche Molecular Systems, Inc., Pleasanton, CA Sofia Shamas, MaxisIT Inc., NJ Chowdagam

More information

Bury Local Care Organisation Provider Alliance

Bury Local Care Organisation Provider Alliance Job Description Post: Project Manager Band: 6 Location/Base: Responsible to: Main Contacts: Bury Town Centre Senior Programme Manager Bury Local Care Organisation Provider Alliance Job Summary The Project

More information

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR

More information

MSCI 689: Career Development for the Biomedical PhD Scientist Introduction to Medical Writing and Drug Development

MSCI 689: Career Development for the Biomedical PhD Scientist Introduction to Medical Writing and Drug Development MSCI 689: Career Development for the Biomedical PhD Scientist Introduction to Medical Writing and Drug Development Danielle K Lewis, PhD April 28, 2017 One-Stop Shop Regulatory Submissions Regulatory Operations

More information

Analyzing which software needs to be utilized to ensure a timely and more automated process

Analyzing which software needs to be utilized to ensure a timely and more automated process Clinical Data Integration & Management March 20 th Program Day One 08:15 Registration and refreshments 08:50 Chair s opening remarks Analyzing which software needs to be utilized to ensure a timely and

More information

POLICY AND PROCEDURE MANUAL

POLICY AND PROCEDURE MANUAL POLICY AND PROCEDURE MANUAL PBRC: POLICY NO. 378.00 ORIGIN DATE: 5/25/2016 IMPACTS: CLINICAL RESEARCH LAST REVISED: 1/1/2017 SUBJECT: SOURCE: PURPOSE PENNINGTON BIOMEDICAL CLINICALTRIALS.GOV POLICY INSTITUTIONAL

More information

Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents

Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents Executive summary 14 Introduction and background to clinical trials 14 Financial considerations

More information

COMPUTER SYSTEMS VALIDATION

COMPUTER SYSTEMS VALIDATION COMPUTER SYSTEMS VALIDATION DOCUMENT NO.: POL007 v1.0 AUTHOR: Lorn Mackenzie ISSUE DATE: 04 AUG 2017 1 INTRODUCTION 1.1 The Academic & Clinical Central Office for Research & Development (ACCORD) is a joint

More information

Validation of Participants

Validation of Participants Validation of Participants Clean Sky 2014 Negotiation Kick-off Info Day Pamela Gorini Henk Van Belle REA - Unit C3 Participant Validation and Support 19th June 2014 Summary Part 1 How to obtain a PIC Part

More information

Quality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A)

Quality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A) Quality Assurance of Investigational Medicinal Products Sue McKenzie PPQA (A) Agenda for Today IMP Regulations - CTD and Annex 13 Role of QP for IMP Challenges of IMP Manufacture for the QP IMP Regulations

More information

ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3

ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3 European Medicines Agency June 2009 EMEA/CHMP/ICH/380636/2009 ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions Step 3 NOTE FOR GUIDANCE

More information

arena that impact on clinical development

arena that impact on clinical development RESEARCH DEVELOPMENT Changes in the regulatory arena that impact on clinical development 23 May 2011 Agenda Voluntary Harmonisation Procedure PIP and Paediatric requirements Changes to EudraCT and European

More information

8/2/2017. Key attributes of scientific excellence: rigor, innovation, and relevance. Medical Physics 3.0. Key Attributes of Scientific Excellence

8/2/2017. Key attributes of scientific excellence: rigor, innovation, and relevance. Medical Physics 3.0. Key Attributes of Scientific Excellence Medical Physics 3.0 in Design Key attributes of scientific excellence: rigor, innovation, and relevance Maryellen Giger, Ph.D. A. N. Pritzker Professor of Radiology / Medical Physics The University of

More information

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick

More information

Author Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document

Author Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document SOP Title: Investigator s Brochure Content, Design, Amendments, Filing & Distribution Author: Clinical Research and Development Office (CRDO) Author Signature: Date: 10 October 2017 The author is signing

More information

University of Virginia Cancer Center

University of Virginia Cancer Center University of Virginia Cancer Center Data and Safety Monitoring Plan for Clinical Research March 18, 2016 Approved: National Cancer Institute April 14 th, 2016 Table of Contents 1. Introduction... 3 2.

More information

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004 Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive

More information

OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET

OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET Badjatya et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 227-232 227 Available online at http://jddtonline.info REVIEW ARTICLE OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS

More information

STANDING COMMITTEE ON FINANCE AND ECONOMIC AFFAIRS. Consideration Of Bill 148 (Fair Workplaces, Better Jobs Act, 2017)

STANDING COMMITTEE ON FINANCE AND ECONOMIC AFFAIRS. Consideration Of Bill 148 (Fair Workplaces, Better Jobs Act, 2017) STANDING COMMITTEE ON FINANCE AND ECONOMIC AFFAIRS Consideration Of Bill 148 (Fair Workplaces, Better Jobs Act, 2017) Submissions of the Association of Canadian Search, Employment & Staffing Services (ACSESS)

More information

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical

More information

Risk-Based Monitoring Update Volume IV

Risk-Based Monitoring Update Volume IV Risk-Based Monitoring Update Volume IV 1. Introduction TransCelerate s Risk-Based Monitoring (RBM) initiative continues to produce tangible outputs during the first half of 2015. The purpose of RBM Update

More information

Good Clinical Practice (GCP) & Clinical Trial Registries

Good Clinical Practice (GCP) & Clinical Trial Registries Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,

More information

A D D E N D U M # Clarification: General QUESTIONS RECEIVED REGARDING TECHNICAL INTERFACE WITH Versaterm CAD AND COUNTY RESPONSES

A D D E N D U M # Clarification: General QUESTIONS RECEIVED REGARDING TECHNICAL INTERFACE WITH Versaterm CAD AND COUNTY RESPONSES A D D E N D U M # 7 October 17, 2017 Address all questions to: Kathi Braeme-Burr, Sr. Procurement Analyst Multnomah County Purchasing 501 SE Hawthorne Blvd. Portland, OR 97214 503-988-7550 E-mail: Kathi.braeme-burr@multco.us

More information

Designing a Disease-Specific Master Protocol

Designing a Disease-Specific Master Protocol Designing a Disease-Specific Master Protocol Lisa M. LaVange, PhD Director, Office of Biostatistics OTS/CDER/FDA Pediatric Master Protocols Workshop September 23, 2016 FDA, White Oak Campus Acknowledgments

More information

2016 CRO LEADERSHIP AWARDS. Page Life Science Leader s readership of pharmaceutical and biopharmaceutical executives have told us about

2016 CRO LEADERSHIP AWARDS. Page Life Science Leader s readership of pharmaceutical and biopharmaceutical executives have told us about List Of Winners Page 28-34 Company Profiles Page 35-42 Life Science Leader s readership of pharmaceutical and biopharmaceutical executives have told us about their struggles in efficiently vetting potential

More information

10:00 Examining the Challenges with Sourcing the Right CRO and Vendors for Global Trials

10:00 Examining the Challenges with Sourcing the Right CRO and Vendors for Global Trials Outsourcing in Clinical Trials East Asia 6 th December 2017 Program Day One 08:30 Registration and Refreshments 08:50 Chair s Opening Speech 09:00 The Key Elements to Success: Learning about the Essential

More information

@TandFOpen. How are subscription publishers making the transition to open access ( OA)?

@TandFOpen. How are subscription publishers making the transition to open access ( OA)? @TandFOpen How are subscription publishers making the transition to open access ( OA)? V Gardner, Open Access Publisher, Taylor & Francis / Routledge UKSG Nov 2013 screen 2 Overview The third age Transition

More information

The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Catalog Addendum

The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Catalog Addendum The University of Texas MD Anderson Cancer Center UTHealth 2016-2018 Catalog Addendum GSBS 2016-18 Catalog Addendum Table of Contents School Name Change... 1 Areas of Research Concentration Changes...

More information

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) 5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) GCP Requirements and Compliance Dr. Katalina Mettke BfArM, Germany Agenda Specialities of Early Development Trials Examples

More information

International Transfers of Personal Data at sanofi-aventis R & D

International Transfers of Personal Data at sanofi-aventis R & D International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF

More information

Sponsorship of Clinical Research Studies

Sponsorship of Clinical Research Studies Sponsorship of Clinical Research Studies Category: Summary: Equality Impact Assessment undertaken: Policy The UK Policy Framework for Health and Social Care 2017 (UKPF) and The Medicines for Human Use

More information

CDISC Standards in the Regulatory Submission Process

CDISC Standards in the Regulatory Submission Process CDISC 2010 CDISC Standards in the Regulatory Submission Process What s New and What s Ahead 26 January 2012 Moderator Frank Newby, CDISC COO CDISC 2012 2011 Webinar Agenda SDTM Amendment 1 Wayne Kubick,

More information

ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon

ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon 9 November 2016 Disclaimer The views and opinions expressed in this presentation are those of the author

More information

Introduction to CMC Regulatory Affairs

Introduction to CMC Regulatory Affairs Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4

More information

Report on recognising organisations as awarding bodies

Report on recognising organisations as awarding bodies Report on recognising organisations as awarding bodies The recognition process February 2008 QCA/08/3569 Contents The recognition process... 3 Background... 3 Current recognition process... 3 Reducing

More information

What is ISO 30300? Who, when, where, why and how to implement

What is ISO 30300? Who, when, where, why and how to implement What is ISO 30300? Who, when, where, why and how to implement Barcelona, October 28th 2011 Carlota Bustelo Judith Ellis Index 1. What is ISO 30300: MSR? a) Background of MSR initiative b) What is a MSR?

More information

Case Studies in Capacity Acquisition:

Case Studies in Capacity Acquisition: Case Studies in Capacity Acquisition: institutional strategies for sourcing Research Data Management (RDM) services Constance Malpas, OCLC Research Research Data and the Evolving Scholarly Record Growing

More information

Non-clinical documentation Overview of Requirements

Non-clinical documentation Overview of Requirements 3 rd EMEA-. Non-clinical Aspects Non-clinical documentation Overview of Requirements EMEA Pre-Authorisation Human Unit 3 rd EMEA-. Non-clinical Aspects Outline Overview of Legal and Regulatory requirements

More information

Asia-Pacific Conference on Transformative Agenda

Asia-Pacific Conference on Transformative Agenda Asia-Pacific Conference on Transformative Agenda Group B Statistics Denmark- set-up 24-26 August 2016, Bangkok Vision We envisage that in 2020 Statistics Denmark is transformed into a generator of data

More information

Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017

Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017 Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market

More information

REGULATORY REQUIREMENTS FOR CLINICAL TRIAL APPROVAL MEDICAL DEVICES DR D DIALE MRS P NKAMBULE. 02 December 2015

REGULATORY REQUIREMENTS FOR CLINICAL TRIAL APPROVAL MEDICAL DEVICES DR D DIALE MRS P NKAMBULE. 02 December 2015 REGULATORY REQUIREMENTS FOR CLINICAL TRIAL APPROVAL MEDICAL DEVICES DR D DIALE MRS P NKAMBULE 02 December 2015 LAYOUT Background to clinical trials Stakeholders in clinical trials Legislative requirements

More information

COMMUNITY SERVICE WORKER 1 COMMUNITY SERVICE WORKER 2

COMMUNITY SERVICE WORKER 1 COMMUNITY SERVICE WORKER 2 B001 B002 Established 01-30-91 COMMUNITY SERVICE WORKER 1 COMMUNITY SERVICE WORKER 2 DEFINITION To provide a variety of services to the community and to assist departments in accomplishing their missions;

More information

-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009

-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009 Introduction to Advanced Therapy Medicinal Products Regulation -Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009 -Directive 2009/120/EC Dr. Maura O Donovan F.R.C.O.G. MA MD M.R.C.P.I. CAT member

More information

POSITION DESCRIPTION SENIOR ENGINEER

POSITION DESCRIPTION SENIOR ENGINEER POSITION DESCRIPTION SENIOR ENGINEER Position Title: Classification: Department: Position Type: Organisational Context: Senior Engineer SGW Enterprise Agreement - SEO Infrastructure and Planning Team Full

More information

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective FAMHP Workshop, Brussels, 2 nd May 2016 Presented by Zahra Hanaizi Product Development

More information

Health research and innovation services

Health research and innovation services Health research and innovation services Health research and innovation services ALIDANS PROVIDES SERVICES AND PRODUCTS FOR RESEARCH AND INNOVATION (R&I) IN THE HEALTH FIELD, THANKS TO A WORLDWIDE NETWORK

More information

Business and Management. Case Study for Paper 1. Reach Out

Business and Management. Case Study for Paper 1. Reach Out Business and Management Case Study for Paper 1 2011 Reach Out 1 Reach Out Task Book. Reach out is your Case study for paper 1. To do well you need to be so familiar with the Case Study that you do not

More information

Comparison of admission rates to neonatal units between PO screening and non-po screening Units

Comparison of admission rates to neonatal units between PO screening and non-po screening Units London - Westminster Research Ethics Committee 4 Minshull Street Manchester M1 3DZ Telephone: 0207 104 8012 Please note: This is the favourable opinion of the REC only and does not allow you to start your

More information

Expanded Access. to Investigational Drugs & Biologics. for Treatment Use

Expanded Access. to Investigational Drugs & Biologics. for Treatment Use SJMHS Research Compliance Office Guidance Document Expanded Access to Investigational Drugs & Biologics for Treatment Use May 2015 1 Expanded Access to Investigational Drugs & Biologics for Treatment Use

More information

Pre-registration Pharmacist National Recruitment Scheme via Oriel Employer Guidance Handbook 2018

Pre-registration Pharmacist National Recruitment Scheme via Oriel Employer Guidance Handbook 2018 Pre-registration Pharmacist National Recruitment Scheme via Oriel Employer Guidance Handbook 2018 Contents 1. Introduction... 3 1.1 Benefits of recruiting nationally... 3 Diagram 1 Pre-registration Pharmacist

More information